Nature Communications

Researchers Use Olink® Explore to Identify Circulating Proteins That May Give Cancer Warning 7 Years Before Diagnosis

Retrieved on: 
torsdag, maj 30, 2024
Genomics, Proteomics, Human genetics, University, Risk, Kingdom of Poland, Nature Communications, Protein, Disease, Blood, Cancer, Research, Genetics, The Road Ahead, Cancer Research UK, Cancer Epidemiology Unit

They were able to pinpoint 371 proteins linked to 19 different cancers, including 107 proteins that were detectable in individuals more than seven years before cancer diagnosis.

Key Points: 
  • They were able to pinpoint 371 proteins linked to 19 different cancers, including 107 proteins that were detectable in individuals more than seven years before cancer diagnosis.
  • "To save more lives from cancer, we need to better understand what happens at the earliest stages of the disease.
  • Data from thousands of people with cancer has revealed really exciting insights into how the proteins in our blood can affect our risk of cancer.
  • Understanding the specific role these proteins play in cancer development and identifying the most reliable ones for testing are crucial next steps.

Octave® Bioscience, Inc. Announces Publication in Nature Communications

Retrieved on: 
onsdag, maj 29, 2024
Health, Communications, Neurology, Research, Science, Publishing, Biotechnology, ACP, EPIC, Patient, Prognosis, UCSF, Nature, Nature Communications, Protein, University, Diagnosis, Disease, Multiple sclerosis, MD, Brigham and Women's Hospital, Harvard Medical School, Biomarker, Manuscript, Hospital, Lead, Medical imaging

Octave® Bioscience, Inc., a leading precision care company that delivers a new standard for managing multiple sclerosis (MS) and other neurodegenerative diseases, today announced the publication of a landmark manuscript in the prestigious journal, Nature Communications.

Key Points: 
  • Octave® Bioscience, Inc., a leading precision care company that delivers a new standard for managing multiple sclerosis (MS) and other neurodegenerative diseases, today announced the publication of a landmark manuscript in the prestigious journal, Nature Communications.
  • Octave’s studies featured in the manuscript included world-class cohorts including CLIMB from Brigham and Women’s, EPIC from UCSF, and the Accelerated Cure Project Biorepository.
  • This work preceded and made possible the analytical and clinical validation studies for Octave’s multi-protein biomarker test, Multiple Sclerosis Disease Activity (MSDA), which were both previously published.
  • In addition, the research indicates multi-protein models have stronger associations than any single protein models.

Autolus Therapeutics Reports First Quarter 2024 Financial Results and Business Updates

Retrieved on: 
fredag, maj 17, 2024
Conference call, UCL, Cardinal Health, Marketing, European Medicines Agency, CD19, FDA, EHA, Multiple myeloma, GD2, Immunotherapy, Research, Flow cytometry, Information technology, University College London, Cardinal, SLE, Conference, BioNTech, MIA, ACS Chemical Biology, MAA, ASH, Clinical trial, Bone marrow, Trial of the century, Nucleus, ADS, ASCO, SME, Minocycline, Marketing Authorisation Application, BCMA, Society, European Hematology Association, Canadian Aviation Regulations, Patient, Nature Communications, T cell, Quarter, Therapy, Engineering, Autoimmune disease, PDUFA, ALL, EMA, TRBC, Abstract, BLA, GMP

Two patients have been enrolled and Autolus continues to expect initial clinical data in late 2024.

Key Points: 
  • Two patients have been enrolled and Autolus continues to expect initial clinical data in late 2024.
  • Enrollment of the initial cohorts are complete and further updates from the MCARTY study are anticipated in H2 2024.
  • In April 2024, Autolus announced the appointment of Mike Bonney as Chairman of the Board, and Ravi Rao M.D., as Non-Executive Director.
  • Financial Results for the Quarter Ended March 31, 2024

Dyadic Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress

Retrieved on: 
tisdag, maj 14, 2024
Cygnus, Partnership, Infection, Analysis, Food, Vaccine, Poultry, Senior, Primate, Note, Hospital, Research, Therapy, Biofuel, RBD, Massachusetts General Hospital, Human, Rabies, Sale, Rabbit, Trial of the century, Pithing, AVATAR, Cattle, SAHPRA, European, Enzyme, Negotiation, Host cell protein, COVID-19, Protein, Safety, Animal, Immortalised cell line, SME, A-DNA, Melamaravakkadu, Insurance, Antigen, Nature Communications, Innovation, Health, Livestock, C1, Convertible, Manuscript, Virology, Transferrin, Webcast, Clinical study report, Phibro Animal Health

JUPITER, Fla., May 14, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a biotechnology company focused on the efficient large-scale manufacture of proteins for use in human and animal vaccines and therapeutics, as well as non-pharmaceutical applications including food, nutrition, and wellness, today announced its financial results for the first quarter of 2024 and highlighted recent Company progress.

Key Points: 
  • ET today
    JUPITER, Fla., May 14, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a biotechnology company focused on the efficient large-scale manufacture of proteins for use in human and animal vaccines and therapeutics, as well as non-pharmaceutical applications including food, nutrition, and wellness, today announced its financial results for the first quarter of 2024 and highlighted recent Company progress.
  • In March 2024, the Company entered into a co-promotion agreement with Biftek Co. for the promotion of growth media supplement for cell culture.
  • The Company is undergoing a beta-lactoglobulin animal-free recombinant whey protein project, expected to begin sampling in the late third quarter.
  • The Company is undergoing a recombinant lactoferrin project, expected to begin sampling the product in the late second or early third quarter.

Tenaya Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

Retrieved on: 
tisdag, maj 14, 2024
Patient, Epidemiology, Cell, Survival, University, PLN, Risk, Nature Communications, PKP2, Cardiomyopathy, Research and development, Workforce, Heart failure, Investment, AAV, Clinical trial, Doctor of Philosophy, ARVC, Therapy, Safety, HCM, Chemistry, Biopsy, CMC, HEK, Gene, Enrollment, Cas9, HDAC6, Society, CRISPR, G&A, Administration, Second Half, Antibody, Pharmaceutical industry

SOUTH SAN FRANCISCO, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today reported financial results for the first quarter ended March 31, 2024, and provided a corporate update.

Key Points: 
  • “The year is off to a strong start for Tenaya,” said Faraz Ali, Chief Executive Officer of Tenaya.
  • Tenaya anticipates sharing initial safety, biopsy and biomarker data from the first cohort of patients in the MyPEAK-1 trial in the second half of 2024.
  • General & Administrative (G&A) Expenses: Year-over year G&A expenses were relatively flat at $8.7 million for the first quarter of 2024 and $8.1 million for the first quarter of 2023.
  • Non-cash stock-based compensation included in G&A expense was $2.2 million for the first quarter of 2024 compared to $1.9 million for the first quarter of 2023.

New Gene-Expression Patterns Linked to Schizophrenia, Bipolar Disorder and Major Depressive Disorder, New Study Shows

Retrieved on: 
onsdag, maj 22, 2024
Mental Health, Health, Genetics, Science, Research, Patient, Bangladesh Technical Education Board, Doctor of Philosophy, TWAS, Gene expression, Hope, Disorder, Medical research, Nature Communications, Depression, NIHR, DSM-IV codes, Disease, Infection, Genome, Mental disorder, Inflammation, Schizophrenia, Bipolar disorder, Multimedia, NIH, Pharmaceutical industry

Through advanced transcriptome-wide association studies (TWAS), researchers can identify unique gene expression profiles to identify new drug targets to treat these disorders.

Key Points: 
  • Through advanced transcriptome-wide association studies (TWAS), researchers can identify unique gene expression profiles to identify new drug targets to treat these disorders.
  • Today, results from a study published by researchers at The Feinstein Institutes for Medical Research and King’s College London in Nature Communications reveal new gene expression patterns linked to common mental health disorders, providing a roadmap for future therapeutic research.
  • Human endogenous retroviruses (HERVs) are non-coding sequences that make up about eight percent of the human genome.
  • The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics’ COVID-19 Vaccine

Retrieved on: 
måndag, maj 20, 2024
COVID-19, Research, Infectious Diseases, Genetics, Clinical Trials, Biotechnology, Health, Pharmaceutical, Science, ASX, Arcturus, Risk, CSL, Nature Communications, Messenger, Therapy, Ageing, Disease, Safety, Public, Person, Senior, Arcturus Therapeutics, ARCT, Vaccine

Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) and Arcturus Therapeutics (Nasdaq: ARCT) today announce Nature Communications has published results from an integrated phase 1/2/3a/3b study evaluating the safety, immunogenicity, and efficacy of ARCT-154, a novel self-amplifying (sa-mRNA) COVID-19 vaccine and the world’s first approved sa-mRNA COVID-19 vaccine.

Key Points: 
  • Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) and Arcturus Therapeutics (Nasdaq: ARCT) today announce Nature Communications has published results from an integrated phase 1/2/3a/3b study evaluating the safety, immunogenicity, and efficacy of ARCT-154, a novel self-amplifying (sa-mRNA) COVID-19 vaccine and the world’s first approved sa-mRNA COVID-19 vaccine.
  • The results demonstrate that two 5 μg doses of ARCT-154, sa-mRNA vaccine, were well-tolerated, immunogenic and provided significant protection against multiple strains of COVID-19.
  • “The results published in Nature Communications demonstrate the efficacy and tolerability of ARCT-154 and add to a growing body of evidence that our sa-mRNA vaccine has the potential to provide significant protection against the pervasive virus, reinforcing our promise to protect public health,” said Jon Edelman, M.D., Senior Vice President, Vaccines Innovation Unit, CSL.
  • “We are thrilled that the results of the ARCT-154 study have been published in the highly respected journal Nature Communications,” said Pad Chivukula, Ph.D., Chief Scientific Officer of Arcturus Therapeutics.

New technique by NUS scientists to transform waste carbon dioxide into high-value chemicals achieves cost reduction of about 30%

Retrieved on: 
tisdag, maj 14, 2024
Carbon, NUS, USD, Nickel, Nature Communications, Climate change, Ethanol, Assistant, National university, Research, Detergent, Disinfectant, CO2, Polymer, Carbon dioxide, Adhesive, Carbon cycle, Multimedia, Plastic, Extractive metallurgy

SINGAPORE, May 14, 2024 /PRNewswire/ -- Addressing the urgent challenge posed by escalating carbon dioxide (CO2) emissions and their impact on climate change, researchers from the National University of Singapore (NUS) have developed a novel technique that significantly advances the conversion of waste carbon dioxide (CO2) into value-added chemicals and fuels.

Key Points: 
  • Carbon capture, utilisation and storage is a fundamental process to a sustainable future, relying on a suite of technologies among which the electrochemical reduction of CO2 is vital.
  • Furthermore, the presence of oxygen impurities in flue gas results in undesired side reactions, which significantly reduces the efficiency of the CO2 reduction process.
  • Utilising this approach, they designed a nickel catalyst boasting exceptional performance for CO2 reduction, achieving an impressive efficiency rate exceeding 99 percent.
  • This versatility offers a broad platform for converting waste CO2 into a diverse range of chemicals, underscoring the technique's adaptability to different industrial needs.

Sensei Biotherapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

Retrieved on: 
torsdag, maj 9, 2024
FDA, Cancer, Nature Communications, Research and development, DLT, MSS, Safety, Pharmacokinetics, Colorectal cancer, CRC, Tumor microenvironment, VISTA, Sensei, IND, Administration, Part-time, ASCO, Keystone, Therapy, Patient, Society, Histology, Neoplasm, Biology, VSIG4, CD39, Annual general meeting, NSCLC, Lung cancer, Pharmaceutical industry

BOSTON, May 09, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today reported financial results for the first quarter ended March 31, 2024, and provided corporate updates.

Key Points: 
  • BOSTON, May 09, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today reported financial results for the first quarter ended March 31, 2024, and provided corporate updates.
  • In January 2024, Sensei announced a realignment of its resources to fully support the Phase 1/2 clinical trial of SNS-101.
  • General and Administrative (G&A) Expenses: G&A expenses were $3.8 million for the quarter ended March 31, 2024, compared to $5.8 million for the quarter ended March 31, 2023.
  • Net Loss: Net loss was $8.0 million for the quarter ended March 31, 2024, compared to $10.2 million for the quarter ended March 31, 2023.

Nuvectis Pharma, Inc. Reports First Quarter 2024 Financial Results and Business Highlights

Retrieved on: 
tisdag, maj 7, 2024
FDA, Mayo Clinic, Nature Communications, Anaplastic lymphoma kinase, Cholangiocarcinoma, Research, Disease, Clinical professor, Patient, AACR, ALK, EGFR, NSCLC, Ovarian cancer, AstraZeneca, Platinum, Lung cancer, Pharmaceutical industry

Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis, commented, "Our clinical development programs for NXP800 and NXP900 continued to advance nicely in the first quarter of 2024.

Key Points: 
  • Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis, commented, "Our clinical development programs for NXP800 and NXP900 continued to advance nicely in the first quarter of 2024.
  • For NXP800, we announced encouraging preliminary data from the Phase 1b study in platinum resistant, ARID1a-mutated ovarian cancer.
  • Cash, and cash equivalents were $19.5 million as of March 31, 2024, compared to $19.1 million as of December 31, 2023.
  • Net loss for the first quarter of 2024 fiscal year included $1.3 million in non-cash stock-based compensation.